Modulation of anti-acetylcholine receptor antibody specificities and of experimental autoimmune myasthenia gravis by synthetic peptides
- PMID: 1282497
- DOI: 10.1016/0165-2478(92)90022-g
Modulation of anti-acetylcholine receptor antibody specificities and of experimental autoimmune myasthenia gravis by synthetic peptides
Abstract
Synthetic peptides corresponding to selected sequences from the nicotinic acetylcholine receptor (AChR) were employed to identify possible antigenic determinants within the receptor which can modulate the anti-AChR response and experimental autoimmune myasthenia gravis (EAMG). Immunization of rabbits with peptides T alpha 73-89, T alpha 351-368, T delta 354-367 and H alpha 351-368, prior to AChR inoculation, affected the course of EAMG in six out of eight rabbits. These six protected rabbits survived three inoculations of AChR and survived for at least five months after the third injection with AChR, whereas control rabbits died following one or two injections of AChR. The survival of peptide-preimmunized rabbits injected with AChR seemed to correlate with the antibody specificities in immunoblots. Following AChR inoculation there was a shift in reactivity, from a subunit-restricted response, to reactivity with all subunits of the receptor. This shift was delayed in protected rabbits. This may indicate that the reactivity with the entire Torpedo receptor molecule represents a loss of tolerance to AChR which culminates in the autoimmune disease, EAMG.
Similar articles
-
Suppression of experimental autoimmune myasthenia gravis by epitope-specific neonatal tolerance to synthetic region alpha 146-162 of acetylcholine receptor.Clin Immunol Immunopathol. 1993 Mar;66(3):230-8. doi: 10.1006/clin.1993.1030. Clin Immunol Immunopathol. 1993. PMID: 7679342
-
Synthetic peptides fail to induce nasal tolerance to experimental autoimmune myasthenia gravis.J Neuroimmunol. 1998 May 1;85(1):96-101. doi: 10.1016/s0165-5728(97)00243-9. J Neuroimmunol. 1998. PMID: 9627002
-
Specificity of the T cell immune response to acetylcholine receptor in experimental autoimmune myasthenia gravis. Response to subunits and synthetic peptides.J Immunol. 1988 Mar 15;140(6):1830-7. J Immunol. 1988. PMID: 2450133
-
On the initial trigger of myasthenia gravis and suppression of the disease by antibodies against the MHC peptide region involved in the presentation of a pathogenic T-cell epitope.Crit Rev Immunol. 2001;21(1-3):1-27. Crit Rev Immunol. 2001. PMID: 11642597 Review.
-
Factors that determine the severity of experimental myasthenia gravis.Ann N Y Acad Sci. 1998 May 13;841:262-82. doi: 10.1111/j.1749-6632.1998.tb10935.x. Ann N Y Acad Sci. 1998. PMID: 9668247 Review.
Cited by
-
Vaccines against myasthenia gravis.Expert Opin Biol Ther. 2005 Jul;5(7):983-95. doi: 10.1517/14712598.5.7.983. Expert Opin Biol Ther. 2005. PMID: 16018742 Free PMC article. Review.
-
Suppression of ongoing experimental myasthenia by oral treatment with an acetylcholine receptor recombinant fragment.J Clin Invest. 1999 Dec;104(12):1723-30. doi: 10.1172/JCI8121. J Clin Invest. 1999. PMID: 10606626 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical